Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report

The introduction of tumor necrosis factor (TNF) antagonists (adalimumab, infliximab, and etanercept) was a major advance and was highly important and beneficial in most rheumatoid arthritis (RA) patients. The adverse effects of this treatment are infrequent, but include opportunistic intracellular i...

Full description

Saved in:
Bibliographic Details
Published in:Medical science monitor 2014-07, Vol.20, p.1227-1231
Main Authors: Kolarz, Bogdan, Majdan, Maria, Darmochwal-Kolarz, Dorota A, Dryglewska, Magdalena
Format: Article
Language:English
Subjects:
Adult
Antibodies, Antiphospholipid - blood
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - pharmacology
Arthritis, Rheumatoid - drug therapy
beta 2-Glycoprotein I - immunology
Cardiolipins - immunology
Enzyme-Linked Immunosorbent Assay
Female
Follow-Up Studies
Humans
Infliximab
Male
Methotrexate - pharmacology
Middle Aged
Preliminary Report
Statistics, Nonparametric
Time Factors
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The introduction of tumor necrosis factor (TNF) antagonists (adalimumab, infliximab, and etanercept) was a major advance and was highly important and beneficial in most rheumatoid arthritis (RA) patients. The adverse effects of this treatment are infrequent, but include opportunistic intracellular infection (especially the reactivation of latent Mycobacterium tuberculosis); exacerbation of demyelinating disorders; and the production of various types of antibodies such as antinuclear antibodies (ANA) or double-stranded DNA autoantibodies (dsDNA) and antiphospholipid antibodies (aPL) such as anti-cardiolipin antibodies (aCL) and anti-B2GP-I antibodies (B2GP-I). The aim of the study was to determine the prevalence of aCL and B2GP-I in IgM and IgG classes, using ELISA tests, during 6 months of follow-up in patients with refractory RA successfully treated with infliximab. We determined the prevalence of aCL and B2GP-I in IgM and IgG classes, using ELISA tests, during 6 months of follow-up in patients with refractory RA successfully treated with infliximab. We observed a statistically important increase only in the group of B2GP-I IgM (p
ISSN:1643-3750
1234-1010
1643-3750
DOI:10.12659/MSM.890270